EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IDRA-21 and Benzothiadiazine AMPA Receptor Modulators: Molecular Pharmacology, Preclinical Cognition and Safety Limitations

Alessia Floramo, Sara Spinelli, Giovanni Luca Cipriano, Ivan Anchesi, Veronica Argento

Cells · 11.11.2026 · 15 (22) · 2048

DOI: 10.3390/cells15222048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 11.11.2026. Verfasst von Alessia Floramo und 4 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Italy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Positive allosteric modulators (PAMs) of AMPA receptors have been investigated as potential cognitive enhancers, but glutamate-dependent potentiation does not eliminate excitotoxic risk. IDRA-21 is an orally active benzothiadiazine derivative with preclinical effects on learning and memory in rodents and non-human primates. This narrative review evaluates its receptor pharmacology, metabolic instability, behavioural evidence and safety limitations, and compares these findings with subsequent medicinal chemistry. IDRA-21 has low affinity for an engineered isolated GluA2 ligand-binding domain and low functional potency in several electrophysiological preparations. Its pharmacology is not restricted to AMPA receptors: direct kainate receptor potentiation, NMDA current inhibition and effects on GABA-mediated currents have also been reported. Hydrolysis to an active metabolite complicates attribution of in vivo effects to the parent compound. The absence of detectable toxicity at selected concentrations in cerebellar cultures contrasts with increased hippocampal injury after global ischemia in rats. Later benzothiadiazines, including BPAM363, show encouraging preclinical profiles, but neither potency alone nor results from a single injury model establish a general safety advantage. No peer-reviewed human administration study of IDRA-21 was identified in the sources examined. IDRA-21 therefore remains a preclinical reference compound whose translational interpretation requires exposure data, receptor-context-specific pharmacology and independently replicated safety studies.

Förderung

  • Ministry of Health, Italy

Zitieren

APA

Floramo, A., Spinelli, S., Cipriano, G. L., Anchesi, I., & Argento, V. (2026). IDRA-21 and Benzothiadiazine AMPA Receptor Modulators: Molecular Pharmacology, Preclinical Cognition and Safety Limitations. Cells, 15(22), 2048. https://doi.org/10.3390/cells15222048

Vancouver

Floramo A, Spinelli S, Cipriano GL, Anchesi I, Argento V. IDRA-21 and Benzothiadiazine AMPA Receptor Modulators: Molecular Pharmacology, Preclinical Cognition and Safety Limitations. Cells. 2026;15(22):2048. doi:10.3390/cells15222048

BibTeX
@article{Floramo2026,
  author = {Floramo, Alessia and Spinelli, Sara and Cipriano, Giovanni Luca and Anchesi, Ivan and Argento, Veronica},
  title = {IDRA-21 and Benzothiadiazine AMPA Receptor Modulators: Molecular Pharmacology, Preclinical Cognition and Safety Limitations},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {2048},
  doi = {10.3390/cells15222048}
}
Kostenlos starten →